Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
JCO Clinical Cancer Informatics|August 28, 2018
Compatibility of Family History Cancer Guidelines With Meaningful Use StandardsAyesha Aziz, Lance Pflieger, Nathaniel O'Connell, et al.Biology Open|February 20, 2016
Co-expression networks in generation of induced pluripotent stem cellsSharan Paul, Lance Pflieger, Warunee Dansithong, et al.Communications Biology|November 27, 2025
Bile acids segregate metabolic syndrome in a cohort of 100 deeply phenotyped horsesCallum G Donnelly, Sichong Peng, Lance Pflieger, et al.Frontiers in Digital Health|February 12, 2024
A framework towards digital twins for type 2 diabetesYue Zhang, Guangrong Qin, Boris Aguilar, et al.Journal of Genetic Counseling|March 8, 2018
Review and Comparison of Electronic Patient-Facing Family Health History ToolsBrandon M Welch, Kevin Wiley, Lance Pflieger, et al.Cancer Cell International|June 23, 2020
Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line modelVince Kornél Grolmusz, Jinfeng Chen, Rena Emond, et al.Cellular Oncology (Dordrecht, Netherlands)|January 13, 2026
Development of an APC and TP53-based duplex sequencing assay to positively predict colorectal cancer response to anti-EGFR therapyMingli Yang, Michael J Schell, Jesse J Salk, et al.Cancers|March 25, 2022
Ras Pathway Activation and MEKi Resistance Scores Predict the Efficiency of MEKi and SRCi Combination to Induce Apoptosis in Colorectal CancerThomas Benjamin Davis, Shilpa Gupta, Mingli Yang, et al.Cancers|November 13, 2021
APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular SubtypesRamya Thota, Mingli Yang, Lance Pflieger, et al.BMC Cancer|March 11, 2022
An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapyMingli Yang, Thomas B Davis, Lance Pflieger, et al.Pageof 2